To the off the shelf cell therapy, the promise of an off the shelf cell therapy is to reach patients only often in care. With an NK cell therapy, I do think it has unique and differentiated safety profile, which allows you to reach into the community setting. But I do think you need to €“ that will require a multiplexed engineered solution. And it will require the delivery of multiple mechanisms of action. And at the highest level, there are some of the decisions that we need to favor our multiplexed engineered product candidates that can synergize and combined with monoclonal antibody that can be given earlier in care, and that potentially do not require intense chemotherapy conditioning as part of the treatment regimen.
Operator: Thank you. Our next question comes from Ben Burnett with Stifel. Your line is open.
Unidentified Analyst: Hi. Good afternoon. This is Karolina on for Ben Burnett. Thank you for taking our question. With regard to your next-gen CD19 CAR NK-cell program FT522 will give you confidence on the level of translation of the enhanced anti-tumor activity and persistence you have observed with your ADR technology and preclinical studies.
Scott Wolchko: Yes. I mean the benefits €“ learner benefits that we have and again, it’s preclinical data. But one of the benefits we have is that an iPSC platform allows you to create very homogeneous consistent product. And so we are able to raise multi generation product candidates against each other for instance, 516, 596, 522. We can do literally head-to-head studies of multiple different product candidates against each other. And I think part of the confidence, as I mentioned, when we had to make the difficult decision with respect to 596, we had very limited clinical data with a three-dose schedule at higher dose levels. I think one of the €“ essentially what gave us confidence though, in addition to we think we need obviously to compete in a competitive landscape, you need a highly differentiated product candidate.
And we think 522 has some very unique features that allow for that differentiation. But certainly all the preclinical experimentation we have done over the past 18 months, raising 516 against 596, against 522 in some very difficult and stringent models, including models that are designed to promote our reactivity, really gave us the confidence to make the decision in advancing 522. I don’t know Bob, if you have anything to add to that?
Bob Valamehr: No. That’s right, Scott. I mean if you split it between potency and avoiding cell rejection. On the potency front 522 leverages the 538 backbone, which 596 did not. And then on the survival factor of an allo environment as Scott mentioned, ADR gives you it a unique ability that other NK cells don’t have.
Operator: Thank you. Our next question comes from Robyn Karnauskas with Truist. Your line is open.
Robyn Karnauskas: Hi, this is Bill on for Robin. Do you envision the possibility of bolstering your competitive edge in multiple myeloma in the near-term by using both 576 and 819 to clear up plasma cells and CD19 progenitor cells while harnessing the best in both?
Scott Wolchko: So, we absolutely have preclinical models where we have combined NK-cells and T-cells. We are not prepared to discuss publicly our strategy for first launching combinations of NK-cells and T-cells. I do think there is significant value in being able to, let’s just say unite, I mean adaptive immunity. And it is the strategy for instance, that we have embedded into, for example, FT825, where we have combat €“ where we have engineered the high affinity CD16 receptor into the backbone of the T-cell. So, I would say based on our experimentation preclinically, we certainly are excited about the potential to unite and innovate an adaptive immunity. We think there is multiple ways to accomplish that. But certainly given the off the shelf nature of our product candidates, creating a defined composition of both cell types, we are delivering for instance, a T-cell followed by an NK-cell vice versa. Both are strategies that I think we can pursue.
